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PURPOSE: High-dose (500 mg orally four times 
daily) vancomycin is considered by many investiga- 
tors to be the most effective treatment for antibiot- 
ic-associated Clostridium difficile colitis. However, 
a lower dosage of 125 or 150 mg given three or four 
times a day has become popular, has been shown to 
be effective, and is less expensive than the high- 
dose regimen. We therefore decided to compare 
two vancomycin dosage regimens in a randomized 
trial. 
PATIENTSANDMETHODS: Thestudyinvolved46 
hospitalized patients with serious underlying dis- 
eases complicated by C. difficile diarrhea or colitis. 
Patients were assigned (according to a table of 
random numbers) to treatment with either 125 or 
500 mg of vancomycin orally four times daily for an 
average of 10 days. 
RESULTS: No significant differences in measur- 
able responses to the two regimens were noted. 
There were no treatment failures. The mean dura- 
tion of diarrhea after initiation of therapy was 
about four days, and almost all patients had no di- 
arrhea after one week. The organism continued to 
be demonstrated in the stools of about 50 percent 
of patients for the first few weeks after completion 
of therapy, and nine (20 percent) patients devel- 
oped a recurrence of their diarrhea1 illness. Vanco- 
mycin was well tolerated by all patients. 
CONCLUSION: Since the dose of 125 mg appeared 
to be as effective as the 500-mg dose, which is more 
expensive, the 125-mg dose is preferred when van- 
comycin is used in treatment of this disease, unless 
the patient is critically ill. 
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D iarrhea is a common and sometimes life-threaten- ing side effect of antibiotic therapy. About 10 per- 
cent of hospitalized adults develop diarrhea after re- 
ceiving antimicrobial drugs for treatment or 
prophylaxis of an infection. Some of these patients can 
be shown to have pseudomembranous colitis caused 
by toxins produced by Clostridium difficile [l]. Diag- 
nosis of this complication is now relatively straightfor- 
ward [2], and treatment consisting of supportive ther- 
apy, discontinuation of the precipitating 
antimicrobial drugs, and the oral administration of 
antimicrobial agents effective against C. difficile is 
usually successful in terminating the illness within a 
week [3]. Vancomycin given orally in a dosage of 500 
mg four times daily has been considered by many in- 
vestigators to be the most effective treatment for this 
disease [4]. However, vancomycin is expensive, often 
costing more than $400 per week, and is not available 
in some parts of the world. Consequently, other forms 
of therapy have been evaluated and found to be effec- 
tive, specifically metronidazole and bacitracin. Metro- 
nidazole given orally has been shown to be as effective 
as vancomycin in one controlled study [5]. However, 
metronidazole-resistant isolates of C. difficile have 
been detected, and treatment failures with it have 
been reported [5-71. Resistance to bacitracin is com- 
mon in our isolates of C. difficile [8], and in addition, 
treatment of the disease with bacitracin has not been 
shown to relieve symptoms as rapidly as vancomycin 
or to be as effective in eliminating the organism [9,10]. 
Consequently, vancomycin is still preferred by many 
for treatment of C. difficile colitis, particularly if the 
patient is severely ill. Since the stool concentrations 
achieved when vancomycin is given orally in a total 
daily dose of 2.0 g are many times those required to 
inhibit all isolates of C. difficile [l,ll], a lower dosage 
of 125 or 150 mg given three or four times per day has 
become popular. These so-called low-dose regimens 
have been shown to be effective [12], and have the 
obvious advantage of being much less expensive than 
the traditional regimen. 
Since the use of low-dose instead of high-dose van- 
comycin regimens has been supported by uncontrolled 
studies and anecdotal case reports [3], we decided to 
compare the therapeutic efficacy of the low-dose and 
high-dose regimens in a controlled manner at our in- 
stitution. The results of this study are the subject of 
this report. 
PATIENTS AND METHODS 
Patients with antibiotic-associated diarrhea at the 
University of Michigan Hospitals or the Ann Arbor 
Veterans Administration Hospital were considered for 
entry into the study after giving informed consent. 
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TABLE I 
Distribution of Treated Patients 
Oral Dose of Vancomycin* 
Diagnosis 
125 mg Four 
Timer/Day 
5Ob mg Four 
Times/D&y Total 
Probable C. difficiile colitis 
Definite C. difici/e colitis 
Total patients 
7 (32) 18 (39) 
15 (68) 28 (61) 
24 (52) 22 (48) 45 (100) 
Numbers in parentheses are percentages. 
TABLE II 
Comparability of Treatment Grou$ 
Characteristic 
Oral Dose of Vancomycin 
0.5 g/Day 2.0 g/Day 
Number of patients 
Mean age in years (range) 
Mean number antibiotics 
given prior to diarrhea 
Number patients who received 
cancer chemotherapy 








recent abdominal surgery 
Other 







Antimicrobials Associated Most Often with Diarrhea* 
Drug Number 










Many of the 46 patients received more than one antimicrobial. 
Diarrhea was defined as the occurrence of liquid stools 
or more than four bowel movements per day for at 
least three days. All patients in the study were judged 
moderately or severely ill, or unresponsive to support- 
ive therapy (patients with mild illness as judged by 
their physicians were treated supportively, and not 
entered into the study). Stools were tested for the 
presence of the cytotoxin (toxin B),of C. cliffMe using 
fibroblast cell cultures [13], and were cultured anaero- 
bically for C. difficile using cycloserine-cefoxitin-fruc- 
tose agar [ 141. All patients in the study had antibiotic- 
associated diarrhea plus at least one stool specimen 
that demonstrated both C. difficilq and its cytotoxin. 
Patients meeting these criteria were further subdi- 
vided into two groups. In the first, patients with endo- 
scopic evidence of colitis were considered to have defi- 
nite colitis. The second group consisted of all other 
patients with diarrhea who had stools positive for the 
organism and toxin B; they were considered to have 
probable colitis (others might prefer that this group be 
designated C. difficile diarrhea). Patients were as- 
signed (according to a table of random numbers) to 
treatment with vancomycin in a dose of either 125 mg 
or 500 mg given orally four times daily, and the physi- 
cians were aware of which regimen their patients re- 
ceived. Infants were treated orally with either 125 or 
500 mg/1.73 m2 body surface area every six hours. Of 
56 patients entered into the study, 10 were later ex- 
cluded from the analysis by one of the investigators 
(who was unaware of the outcome of treatment) be- 
cause of nonadherence to the protocol (two), lack of 
substantiation of the diagnosis (six), or death within 
48 hours (two) because of an underlying disease (i.e., 
not due to diarrhea or colitis). Four of 28 patients 
treated with 500 mglday of vancomycin, and six of 28 
patients treated with 2.0 g/day were excluded from the 
study; one patient in each group was excluded because 
of death within the first 48 hours. No patient had ileus, 
toxic megacolon, or impending perforation. In no case 
was it necessary to treat a patient with a parenteral 
antimicrobial agent for diarrhea because they were 
unable to receive oral vancomycin, but in a few cases 
vancoinycin had to be administered through a naso- 
gastric tube, which was clamped intermittently when 
suction was being applied. When vancomycin was be- 
gun, the antimicrobial regimen thought to have pre- 
cipitated the diarrhea was either discontinued or re- 
placed by an alternative regimen. No patients received 
antiperistaltic agents or other symptomatic treatment 
for diarrhea while receiving vancomycin, but fluids 
and electrolytes were replaced as needed. Diarrhea 
was considered to have ceased either when patients 
stated their bowel function was normal, or when they 
were having three or fewer movements a day and their 
stools were semi-formed. Patients whose diarrhea 
ceased within seven days after vancomycin was begun 
were considered to have a good response; patients 
whose diarrhea ceased but after seven days of treat- 
ment were considered simply to have responded. 
RESULTS 
Table I characterizes and compares the 46 patients 
retained in the study. Eighteen (39 percent) had prob- 
able C. difficile colitis and 28 (61 percent of the treated 
patients) had definite C. difficile colitis; all of the lat- 
ter patients had endoscopically proven pseudomem- 
branous colitis. In fact, all patients who underwent 
endoscopy had definite colitis. Twenty-four (52 per- 
cent) received the low dose of vancomycin (500 mgl 
day) and 22 (48 percent) received the high dose (2.0 g/ 
day). There were no statistically significant differ- 
ences in the distribution of patients given the two 
dosage regimens in the groups in Table I (p >0.05). 
Table II compares other characteristics of the study 
groups. All but one of the patients were adults; the 
mean ages of the two groups were 56 (low dose) and 52 
years (high dose). One infant with probable colitis was 
entered into the study and responded well to treat- 
ment (20 mg vancomycin given four times a day). This 
was the equivalent of the 125-mg dose (based upon 
body surface area). The mean number of antibiotics 
received in the hospital per patient prior to onset of 
diarrhea, the number who received cancer chemo- 
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TABLE IV 











Number of Responses 







Number of Responses 










Both colitis groups 0.5 g 21 (87.5)* 
2.og 21 (95.4)* ;: 
Total patients - 42 (91.3) 4 (8.7) 46 
*x* = 3.0, p >0.05. 
t x2 = 1.04, p >0.05. 
*X2 = 1.36, p >0.05. 
therapy, and the number who had serious underlying 
diseases, abdominal surgery, or intra-abdominal dis- 
eases did not differ significantly between the two 
groups. On the basis of these data, the two dosage 
groups were judged to be comparable. The antibiotics 
received prior to diarrhea are shown in Table III. 
Parenteral cephalosporins were most often implicat- 
ed, and there were no significant differences in specific 
antibiotics between the two groups. 
The responses to treatment with vancomycin by di- 
agnostic group and by dosage regimen are summarized 
in Table IV. Overall, 91 percent of patients had a good 
response to therapy, with cessation of diarrhea within 
one week (Figure 1). There were no treatment fail- 
ures. All patients improved and responded with cessa- 
tion of diarrhea by 12 days. There were no significant 
differences in response rates according to the dosage 
regimen. The good response rate for definite antibiot- 
ic-associated colitis was 96 percent, and the rate was 
83 percent for probable antibiotic-associated colitis. 
This difference was not statistically significant (x2 = 
2.25; p >0.05). In subsequent analyses, these two cate- 
gories have been grouped together. 
As shown in Table V, the mean duration of abdomi- 
nal pain after the start of therapy for all patients was 
2.5 f 1.0 (SE) days, and the mean duration of diarrhea 
after treatment was 4.1 f 1.6 (SE) days, with a range of 
two to 12 days. Patients who received the lower dose of 
vancomycin had a slightly more rapid resolution of 
both pain and diarrhea, as shown for diarrhea in Fig- 
ure 1, but the differences were neither statistically nor 
clinically significant. 
Because it was our clinical impression that elderly 
patients with antibiotic-associated colitis tend to have 
a more severe illness than do young patients, the effect 
of dose of vancomycin upon the rapidity of resolution 
of diarrhea for patients 60 years of age or less was 
compared with that of patients greater than 60 years 
of age. There was no significant difference in the ra- 
pidity of cessation of diarrhea in patients over 60 years 
who received the low dose of vancomycin (mean of 3.6 
days) as compared with the high dose (mean 3.4 days). 
In fact, both means in patients over 60 were lower than 
the means for all patients, 4.1 days (Table V). Thus, it 
was not possible to confirm our subjective clinical im- 
pression that the disease was more severe in the elder- 
0 500 mg 4 times/day 
0 125 mg 4 times/day 
DAY OF TREATMENT 
Figure 1. Cessation of diarrhea (rate) after institution of therapy with 
oral vancomycin. 
TABLE V 
Duration of Symptoms after Start of Treatment (Mean f 
SE in Days) 
Daily Dose Number Abdominal Pain Diarrhea 
0.5g ;z 2.1 f 0.9 3.8 f 1.4 
2.0 g 2.7 f 1.5 4.3 f 1.8 
Total 46 2.5 f 1.0 4.1 f 1.6 
ly, using criteria such as height of fever, number of 
stools a day, and so forth. Neither were there any 
objective or subjective differences in severity of the 
diarrhea in the two dosage groups. There were not 
enough patients with severe diarrhea in this study to 
permit separate analysis, but there did not appear to 
be a slower response in patients with profuse diarrhea 
and more severe illness. 
Most patients were treated with vancomycin for 
about 10 days, with a range of five to 15 days. The 
duration of therapy was decided by the medical staff 
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TABLE VI 
Duration of Therapy with Vancomycin in Days 
Mean 
Range 
0.5 g/Day 2.0 g/Day 
10.6 10.1 
7-12 5-15 
primarily responsible for the care of these patients, 
and based upon their clinical responses. There were no 
significant differences in the duration of therapy with 
vancomycin in the two groups, as shown in Table VI. 
This equivalence in duration of therapy further sup- 
ports the equal efficacy of the two regimens. Four pa- 
tients (all women) in this study were treated for more 
than 10 days with oral vancomycin because of a slow 
response to the drug. Three had received the low dose 
and one had received the high dose. Two of the women 
had underlying chronic inflammatory bowel diseases, 
and the other one had diabetes mellitus with a history 
of chronic diarrhea. These underlying diseases may 
have contributed to prolongation of diarrhea. 
Nineteen patients, all of whom were asymptomatic, 
were available for follow-up studies and had stool cul- 
tures performed two to six weeks after discontinuation 
of vancomycin. There were no significant differences 
in the post-treatment carriage rates with the two regi- 
mens. Four of nine patients who received the 125-mg 
dose and six of 10 who received the 500-mg dose had 
positive results of stool cultures in convalescence. The 
overall rate of positive stool cultures in asymptomatic 
patients available for post-treatment culture was 56 
percent (10 of 19). Of the 10 patients who were shown 
to be post-treatment carriers of C. difficile, five (50 
percent) developed a recurrence of their disease within 
the first few months following the completion of thera- 
py with vancomycin, usually spontaneously (no antibi- 
otics administered). Post-treatment culture speci- 
mens had not been obtained from four other persons 
who experienced a recurrence. A total of nine recur- 
rences developed in the 46 patients (20 percent). Most 
patients who had a recurrence did so within six weeks 
after the discontinuation of therapy. Five patients 
who developed a recurrence had received the 125-mg 
dose and four had received the 500-mg dose. Overall, 
the rate of symptomatic recurrence was 20 percent, 
and the difference in frequency with the low- (20.8 
percent) and the high-dose (18.9 percent) regimens 
was not statistically significant. Vancomycin-resistant 
(minimal inhibitory concentration greater than 16 pgl 
ml) C. difficile isolates were not detected during re- 
lapses. Patients with relapses were not re-entered into 
the study, but were re-treated with a short course of 
oral vancomycin in a dosage chosen by their physician. 
All responded promptly to this measure and there 
were no further recurrences. 
Vancomycin was tolerated well by all patients, and 
none showed any evidence of systemic toxicity. 
COMMENTS 
This study did not show a significant difference in 
the efficacy of total daily oral doses of 500 mg and 
2,000 mg of vancomycin given in four divided doses in 
the therapy of adults with antibiotic-associated diar- 
rhea and/or colitis caused by C. difficile. There were 
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no treatment failures with either dose. As measured by 
the rapidity of cessation of abdominal pain (mean 2.5 
days) or diarrhea (mean 4.1 days), the rate of response 
by seven days (about 90 percent), the frequency of side 
effects (essentially none), the duration of therapy 
(usually about 10 days), the frequency of positive cul- 
tures after treatment (mean of 56 percent in those 
available for post-treatment cultures), and the rate of 
recurrences or relapses (20 percent), no significant dif- 
ferences were noted between the two dosage regimens. 
Although almost 10 percent of patients continued to 
have diarrhea for more than seven days after therapy 
was started, the condition of aZE patients had clearly 
improved within one week. Thus, diarrhea persisting 
for seven days or more after therapy with vancomycin 
was begun did not by itself indicate a failure of treat- 
ment. 
Although these findings do not prove equivalence of 
the two regimens, they are consistent with predictions 
of equivalence based upon: (1) the minimal systemic 
absorption of vancomycin when it is administered 
orally, (2) predicted stool concentrations (100 pg/ml or 
more) with the lower dose even when there is diarrhea 
amounting to 5 liters/day, and (3) the fact that in vitro 
concentrations of vancomycin equal to or less than 5 
rglml are sufficient to inhibit C. difficile isolates ob- 
tained from patients with pseudomembranous colitis 
[14,15]. Vancomycin-resistant isolates of C. difficile 
have never been detected. Although stool concentra- 
tions of vancomycin were not measured in this study, 
it is likely the concentrations achieved in stools using 
the lower dose were many times (at least 20) greater 
than those required for inhibition of C. difficile. Thus, 
one advantage of vancomycin over less expensive al- 
ternative therapies such as metronidazole and bacitra- 
tin relates to the fact that resistant isolates of both of 
the latter have been detected [7,16]. 
In interpreting our results, there are two points that 
should be noted. First, it is possible that the higher (or 
less likely the lower) dose is actually better, but that 
its superiority was masked because there were too few 
patients in the study. When the observed response 
rates (Figure 1) and their variability are considered, 
detection of a clinically significant difference between 
the two groups in frequency of diarrhea at four or 
seven days would have required a study involving ap- 
proximately 200 or 1,000 patients, respectively 1171. 
Such a study is unlikely to come from a single institu- 
tion. This theoretical consideration as well as our ob- 
served results demonstrating no clinically significant 
differences in responses with these doses will probably 
discourage any further attempt to conduct a multi- 
center study on the issue. Second, it is possible that 
there may be a difference between the two regimens 
that is evident only with very “sick” or “toxic” pa- 
tients. Patients in this study were judged to be moder- 
ately or severely ill, but patients were not stratified for 
severity of illness prior to entry into the study. In 
retrospect, only a small number (five to 10) of our 
patients could be considered severely ill. If there is 
reason to question the efficacy of the lower dose in 
severely ill patients, the higher dose of vancomycin 
could be used, and is in our opinion preferred over 
metronidazole in this setting. However, severe illness 
is not a problem with the vast majority of patients with 
C. difficile colitis, especially if the diagnosis is made 
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early in the disease. Since completing this study, we 
have used the lower dose preferentially at the Univer- 
sity of Michigan Hospitals, and have not encountered 
any treatment failures with the drug. 
From the standpoint of cost, the lower dose of van- 
comycin offers some obvious advantages. The current 
local acquisition cost for the vancomycin capsules 
available for oral treatment in a dosage of 125 mg four 
times daily for seven days is $111; for 500 mg four 
times daily it is $444. Although little or no vancomycin 
is absorbed when it is given orally, even in the presence 
of colitis [1,3,18], therapeutic serum concentrations 
have been detected in patients with severe renal fail- 
ure [19]. This risk, which is mostly a theoretical one, is 
further reduced when the lower dose (125 mg) is used, 
and it is therefore preferred in patients with renal 
failure. 
For the patient with mild or moderately severe C. 
difficile colitis in whom specific treatment is desir- 
able, it is likely, although still speculative, that low- 
dose vancomycin (0.5 g/day) is as effective as metroni- 
dazole [5]. It is also potentially less toxic [20]. Cost 
considerations favor metronidazole for treatment of 
these patients. The local acquisition cost for metroni- 
dazole (250 mg orally four times daily) is only $3. For 
more seriously ill patients, oral vancomycin is still the 
drug of choice in our opinion because of possible resis- 
tance of the organism to metronidazole or bacitracin, 
and because metronidazole may be absorbed com- 
pletely from the small intestines of patients with im- 
pending ileus. Some would recommend the addition of 
intravenous metronidazole and/or vancomycin to the 
regimen in critically ill patients with ileus. For those 
unable to tolerate metronidazole because of real or 
potential toxicity, low-dose vancomycin is preferred 
for adults, and bacitracin is an alternate. However, 
similar toxicity was seen with vancomycin and metro- 
nidazole in the study of Teasley et al [5]. Since both 
post-treatment intestinal carriage of C. difficile and 
relapses or recurrences of C. difficile colitis have been 
observed with all forms of therapy (vancomycin, me- 
tronidazole, or bacitracin), and at about the same fre- 
quency [16], these factors do not provide good reasons 
to choose between the regimens. 
Other investigational drugs that are active against 
C. difficile, such as teicoplanin and daptomycin, may 
have practical advantages over vancomycin or metro- 
nidazole, but it is unlikely they will be superior in 
effectiveness. Further studies are needed with these 
potentially useful agents. 
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